300267 尔康制药
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.631-8.044-3.9510.928-14.841
总资产报酬率 ROA (%)0.545-6.993-3.4460.814-13.090
投入资产回报率 ROIC (%)0.560-7.235-3.6060.856-13.752

边际利润分析
销售毛利率 (%)26.13527.52320.42422.22023.341
营业利润率 (%)7.419-32.521-11.5930.737-36.619
息税前利润/营业总收入 (%)7.853-34.032-11.1511.634-37.606
净利润/营业总收入 (%)6.772-34.453-12.4421.982-35.710

收益指标分析
经营活动净收益/利润总额(%)58.20719.10756.875-66.062-4.149
价值变动净收益/利润总额(%)10.00914.2774.561108.424-2.050
营业外收支净额/利润总额(%)1.3494.511-3.91720.5963.219

偿债能力分析
流动比率 (X)2.7102.4342.8692.8833.901
速动比率 (X)1.6251.5831.7231.7502.468
资产负债率 (%)13.84715.33812.21113.74010.278
带息债务/全部投入资本 (%)8.73910.0437.0757.7155.016
股东权益/带息债务 (%)1,023.550877.5751,295.7901,177.6521,870.734
股东权益/负债合计 (%)629.147557.642722.818627.794868.961
利息保障倍数 (X)23.571-1,336.839-2,082.7662.314-162.266

营运能力分析
应收账款周转天数 (天)31.06133.53824.51530.81143.507
存货周转天数 (天)219.133281.647191.927190.048154.502